Clinical Trial: A Trial of HRS-5965 Capsule in Primary IgA Nephropathy

U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07014826) titled 'A Trial of HRS-5965 Capsule in Primary IgA Nephropathy' on May 22.

Brief Summary: This multicenter, randomized, double-blind, parallel, placebo-controlled study is being conducted to evaluate the efficacy, and safety of HRS-5965 capsule for primary IgA nephropathy.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Primary IgA Nephropathy

Intervention: DRUG: HRS-5965

HRS-5965

DRUG: Placebo

Placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Chengdu Suncadia Medicine Co., Ltd.

Published by HT Digital Content Services with permission from Health Daily Digest....